Donald Engelman

Donald Max Engelman
EducationYale University, King's College London, Reed College Edit this on Wikidata
OccupationsBiochemist, biophysicist, university teacher, scientist Edit this on Wikidata
Employer
Awards
Scientific career
Born1941 (age 84–85)
EducationReed College, Yale University
AwardsGuggenheim fellow
FieldsCancer drugs and treatments
WorkplacesYale University
ThesisSolubilization and Aggregation Properties of Membrane Components from Mycoplasma laidlawii (1968)
Doctoral students
Mark A. Lemmon
Websitemedicine.yale.edu/lab/engelman/ Edit this on Wikidata

Donald Max Engelman (born 1941) is Higgins Professor of Biochemistry at Yale University. He is a member of the National Academy of Sciences (1997), fellow of the American Academy of Arts and Sciences, a fellow of the National Institutes of Health, and has been a Guggenheim fellow. He served as the editor of the Annual Review of Biophysics and Biophysical Chemistry (1984–1993).

He is a director of the Stryker Corporation. He is involved in the creation of new cancer drugs and treatments. For example, Engelman is involved in research to use peptides to aid in destroying tumors.

Administration, advising, and consulting

Engelman has served as Director of Biological Sciences at Yale, an advisor to the Brookhaven National Laboratory, and a consultant to the Los Alamos National Laboratory. He also served as Acting Dean of Yale College in 1991.

Education

Engelman is a graduate (and trustee) of Reed College receiving his degree in physics. He then earned his Ph.D. in molecular biophysics at Yale University in 1969.

Engelman Lab

Engelman directs the Engelman Laboratory at Yale focused on the biophysics of biological membranes. His group is best known for elucidating the mechanism of pH Low Insertion Peptide (pHLIP) to form trans-membrane helices.

Patents

Engelman holds six United States patents for his discoveries.